September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more
Prelude Therapeutics, a Phase 1 biotech developing PRMT5 inhibitors for difficult to treat cancers, raised $158 million by offering 8.3 million shares at $19, the high end of the range of $17 to $19. The Wilmington, DE-based company plans to list on the...read more
Prelude Therapeutics, a phase 1 biotech developing small molecule therapies for cancer, announced terms for its IPO on Monday.
The Wilmington, DE-based company plans to raise $150 million by offering 8.3 million shares at a price range of $17 to $19. At the...read more
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more
US IPO Weekly Recap: Health and tech dominate the calendar in an 11 IPO week
September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more
Cancer biotech Prelude Therapeutics prices IPO at $19, the high end of the range
Prelude Therapeutics, a Phase 1 biotech developing PRMT5 inhibitors for difficult to treat cancers, raised $158 million by offering 8.3 million shares at $19, the high end of the range of $17 to $19. The Wilmington, DE-based company plans to list on the...read more
Oncology biotech Prelude Therapeutics sets terms for $150 million IPO
Prelude Therapeutics, a phase 1 biotech developing small molecule therapies for cancer, announced terms for its IPO on Monday. The Wilmington, DE-based company plans to raise $150 million by offering 8.3 million shares at a price range of $17 to $19. At the...read more
US IPO Weekly Recap: The September IPO market kicks off with a quiet week
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more